Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer.


Increased ploidy is common in tumors but treatments for tumors with excess chromosome sets are not available. Here, we characterize high-ploidy breast cancers and identify potential anticancer compounds selective for the high-ploidy state. Among 354 human breast cancers, 10% have mean chromosome copy number exceeding 3, and this is most common in triple-negative and HER2-positive types. Women with high-ploidy breast cancers have higher risk of recurrence and death in two patient cohorts, demonstrating that it represents an important group for improved treatment. Because high-ploidy cancers are aneuploid, rather than triploid or tetraploid, we devised a two-step screen to identify selective compounds. The screen was designed to assure both external validity on diverse karyotypic backgrounds and specificity for high-ploidy cell types. This screen identified novel therapies specific to high-ploidy cells. First, we discovered 8-azaguanine, an antimetabolite that is activated by hypoxanthine phosphoribosyltransferase 1 (HPRT1), suggesting an elevated gene-dosage of HPRT1 in high-ploidy tumors can control sensitivity to this drug. Second, we discovered a novel compound, 2,3-diphenylbenzo[g]quinoxaline-5,10-dione (DPBQ). DPBQ activates p53 and triggers apoptosis in a polyploid-specific manner, but does not inhibit topoisomerase or bind DNA. Mechanistic analysis demonstrates that DPBQ elicits a hypoxia gene signature and its effect is replicated, in part, by enhancing oxidative stress. Structure-function analysis defines the core benzo[g]quinoxaline-5,10 dione as being necessary for the polyploid-specific effects of DPBQ. We conclude that polyploid breast cancers represent a high-risk subgroup and that DPBQ provides a functional core to develop polyploid-selective therapy. Mol Cancer Ther; 15(1); 48-59. ©2015 AACR.

DOI: 10.1158/1535-7163.MCT-15-0527

7 Figures and Tables

Cite this paper

@article{Choudhary2016IdentificationOS, title={Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer.}, author={Alka Choudhary and Brittany Zachek and Robert F Lera and Lauren M. Zasadil and Amber L. Lasek and Ryan A Denu and Hyunjung Kim and Craig Kanugh and Jennifer J.S. Laffin and Josephine M. Harter and Kari B. Wisinski and Sandeep Saha and Beth A. A. Weaver and Mark E Burkard}, journal={Molecular cancer therapeutics}, year={2016}, volume={15 1}, pages={48-59} }